Analgesic effect of quetiapine in a mouse model of cancer-induced bone pain
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Cancer-induced bone pain (CIBP) is one of the most common pains in patients with advanced neoplasms. Because of treatment-associated side effects, more than half of cancer patients are reported to have inadequate and undermanaged pain control. New mechanism-based therapies must be developed to reduce cancer pain. Quetiapine is a commonly used atypical antipsychotic drug. We report a study of the potential analgesic effects of quetiapine in a mouse model of CIBP and examine the mechanism of bone pain by analyzing the expression of various nociceptors. Methods: Fifteen male C3H/HeN mice were arbitrarily divided into five groups: control and, CIBP with no treatment, quetiapine treatment, opioid treatment, and melatonin treatment. The mice were tested for mechanical hyperalgesia by determining the nociceptive hind paw withdrawal pressure threshold. Tissues from tibia were removed and subjected to quantitative and qualitative evaluations of transient receptor potential vanilloid 1 (TRPV1), TRPV4, acid-sensing ion channel 1 (ASIC1), ASIC2, and ASIC3 expression. Results: Paw withdrawal pressure threshold was improved in the quetiapine treatment group compared with the CIBP group. Expression of TRPV1, TRPV4, ASIC1, ASIC2, and ASIC3 in the CIBP with quetiapine treatment group was significantly lower than that in the CIBP group. Conclusions: Our results suggest an analgesic effect of quetiapine in the CIBP animal model and implicate TRPV and ASICs as potential targets for cancer pain management.
Abstract
Background/Aims: Cancer-induced bone pain (CIBP) is one of the most common pains in patients with advanced neoplasms. Because of treatment-associated side effects, more than half of cancer patients are reported to have inadequate and undermanaged pain control. New mechanism-based therapies must be developed to reduce cancer pain. Quetiapine is a commonly used atypical antipsychotic drug. We report a study of the potential analgesic effects of quetiapine in a mouse model of CIBP and examine the mechanism of bone pain by analyzing the expression of various nociceptors. Methods: Fifteen male C3H/HeN mice were arbitrarily divided into five groups: control and, CIBP with no treatment, quetiapine treatment, opioid treatment, and melatonin treatment. The mice were tested for mechanical hyperalgesia by determining the nociceptive hind paw withdrawal pressure threshold. Tissues from tibia were removed and subjected to quantitative and qualitative evaluations of transient receptor potential vanilloid 1 (TRPV1), TRPV4, acid-sensing ion channel 1 (ASIC1), ASIC2, and ASIC3 expression. Results: Paw withdrawal pressure threshold was improved in the quetiapine treatment group compared with the CIBP group. Expression of TRPV1, TRPV4, ASIC1, ASIC2, and ASIC3 in the CIBP with quetiapine treatment group was significantly lower than that in the CIBP group. Conclusions: Our results suggest an analgesic effect of quetiapine in the CIBP animal model and implicate TRPV and ASICs as potential targets for cancer pain management.
참고문헌 (20)
- Goudas LC, "The epidemiology of cancer pain", Cancer Invest, 23, pp.182~190 (2005)
- Portenoy RK, "Management of cancer pain", Lancet, 353, pp.1695~1700 (1999)
- Levy MH., "Pharmacologic treatment of cancer pain", N Engl J Med, 335, pp.1124~1132 (1996)
- de Wit R, "The Amsterdam Pain Management Index compared to eight frequently used outcome measures to evaluate the adequacy of pain treatment in cancer patients with chronic pain", Pain, 91, pp.339~349 (2001)
- Meuser T, "Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology", Pain, 93, pp.247~257 (2001)
- Schwei MJ, "Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain", J Neurosci, 19, pp.10886~10897 (1999)
- Mantyh PW, "Molecular mechanisms of cancer pain", Nat Rev Cancer, 2, pp.201~209 (2002)
- Fujii Y, "TRP channels and ASICs mediate mechanical hyperalgesia in models of inflammatory muscle pain and delayed onset muscle soreness", Pain, 140, pp.292~304 (2008)
- Ikeuchi M, "Role of ASIC3 in the primary and secondary hyperalgesia produced by joint inflammation in mice", Pain, 137, pp.662~669 (2008)
- Xu TL, "Calcium-permeable acid-sensing ion channel in nociceptive plasticity: a new target for pain control", Prog Neurobiol, 87, pp.171~180 (2009)
- Julius D, "Molecular mechanisms of nociception", Nature, 413, pp.203~210 (2001)
- Arvanitis LA, "Multiple fixed doses of “Seroquel”(quetiapine) in patients with acute exacerbation of schizophrenia:a comparison with haloperidol and placebo: the Seroquel Trial 13 Study Group", Biol Psychiatry, 42, pp.233~246 (1997)
- Bianchi M, "Antidepressant drugs and experimental inflammation", Pharmacol Res, 33, pp.235~238 (1996)
- Taler M, "Evidence for an inhibitory immunomodulatory effect of selected antidepressants on rat splenocytes: possible relevance to depression and hyperactive-immune disorders", Int Immunopharmacol, 8, pp.526~533 (2008)
- Kim H, "Anti-inflammatory effect of quetiapine on collagen-induced arthritis of mouse", Eur J Pharmacol, 678, pp.55~60 (2012)
- Lozano-Ondoua AN, "Cancer-induced bone pain: mechanisms and models", Neurosci Lett, 557 Pt A, pp.52~59 (2013)
- atkins LR, "Characterization of cytokine-induced hyperalgesia", Brain Res, 654, pp.15~26 (1994)
- Jimenez-Andrade JM, "Bone cancer pain", Ann N Y Acad Sci, 1198, pp.173~181 (2010)
- Mantyh PW., "Cancer pain and its impact on diagnosis, survival and quality of life", Nat Rev Neurosci, 7, pp.797~809 (2006)
- Zhang RX, "Spinal glial activation in a new rat model of bone cancer pain produced by prostate cancer cell inoculation of the tibia", Pain, 118, pp.125~136 (2005)